Literature DB >> 17103189

Successful unrelated bone marrow transplantation in a child with chronic granulomatous disease complicated by pulmonary and cerebral granuloma formation.

Catharina Schuetz1, Manfred Hoenig, Ansgar Schulz, Min Ae Lee-Kirsch, Joachim Roesler, Wilhelm Friedrich, Horst von Bernuth.   

Abstract

We report on a 6-year-old boy with chronic granulomatous disease (CGD) complicated by chronic inflammatory reactions with formation of large pulmonary granuloma as well as intracerebral lesions. Bone marrow transplantation (BMT) from an unrelated donor led to stable reconstitution, to rapid resolution of pulmonary granuloma, and to rapid resolution of intracerebral lesions.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17103189     DOI： 10.1007/s00431-006-0317-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  17 in total

1.  Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils.

Authors:  Shyra Gardai; Ben B Whitlock; Cheryl Helgason; Dan Ambruso; Valerie Fadok; Donna Bratton; Peter M Henson
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

2.  Inhibition of human neutrophil IL-8 production by hydrogen peroxide and dysregulation in chronic granulomatous disease.

Authors:  Julie A Lekstrom-Himes; Douglas B Kuhns; W Gregory Alvord; John I Gallin
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

3.  Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease.

Authors:  J Roesler; S Heyden; M Burdelski; H Schäfer; H W Kreth; R Lehmann; D Paul; J Marzahn; M Gahr; A Rösen-Wolff
Journal:  Exp Hematol       Date:  1999-03       Impact factor: 3.084

4.  Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils.

Authors:  Y Kasahara; K Iwai; A Yachie; K Ohta; A Konno; H Seki; T Miyawaki; N Taniguchi
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

Review 5.  Chronic granulomatous disease presenting with disseminated intracranial aspergillosis.

Authors:  Abdul Alsultan; Marc S Williams; Sam Lubner; Frederick D Goldman
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

6.  Long-term follow-up and outcome of 39 patients with chronic granulomatous disease.

Authors:  J Liese; S Kloos; V Jendrossek; T Petropoulou; U Wintergerst; G Notheis; M Gahr; B H Belohradsky
Journal:  J Pediatr       Date:  2000-11       Impact factor: 4.406

7.  Brain lesions in chronic granulomatous disease.

Authors:  M G Hadfield; N R Ghatak; F J Laine; E C Myer; F S Massie; W M Kramer
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

8.  Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD).

Authors:  Joanne R Brown; David Goldblatt; Joanna Buddle; Louise Morton; Adrian J Thrasher
Journal:  J Leukoc Biol       Date:  2003-05       Impact factor: 4.962

Review 9.  Current treatment options for chronic granulomatous disease.

Authors:  David Goldblatt
Journal:  Expert Opin Pharmacother       Date:  2002-07       Impact factor: 3.889

10.  Primary Candida meningitis and chronic granulomatous disease.

Authors:  J Fleischmann; J A Church; R I Lehrer
Journal:  Am J Med Sci       Date:  1986-05       Impact factor: 2.378
View more
  8 in total

Review 1.  Hematologically important mutations: X-linked chronic granulomatous disease (third update).

Authors:  Dirk Roos; Douglas B Kuhns; Anne Maddalena; Joachim Roesler; Juan Alvaro Lopez; Tadashi Ariga; Tadej Avcin; Martin de Boer; Jacinta Bustamante; Antonio Condino-Neto; Gigliola Di Matteo; Jianxin He; Harry R Hill; Steven M Holland; Caroline Kannengiesser; M Yavuz Köker; Irina Kondratenko; Karin van Leeuwen; Harry L Malech; László Marodi; Hiroyuki Nunoi; Marie-José Stasia; Anna Maria Ventura; Carl T Witwer; Baruch Wolach; John I Gallin
Journal:  Blood Cells Mol Dis       Date:  2010-08-21       Impact factor: 3.039

Review 2.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

3.  Advances in treatment for chronic granulomatous disease.

Authors:  Elizabeth M Kang; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 4.  Immunodeficiencies.

Authors:  M Ballow; L Notarangelo; B Grimbacher; C Cunningham-Rundles; M Stein; M Helbert; B Gathmann; G Kindle; A K Knight; H D Ochs; K Sullivan; J L Franco
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

5.  Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease.

Authors:  Yasuo Takeuchi; Emiko Takeuchi; Takashi Ishida; Masafumi Onodera; Hiromitsu Nakauchi; Makoto Otsu
Journal:  Int J Hematol       Date:  2015-04-29       Impact factor: 2.490

6.  Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease--single centre experience.

Authors:  Jolanta Goździk; Anna Pituch-Noworolska; Szymon Skoczeń; Wojciech Czogała; Anna Wędrychowicz; Jarosław Baran; Aleksandra Krasowska-Kwiecień; Oktawiusz Wiecha; Marek Zembala
Journal:  J Clin Immunol       Date:  2011-03-09       Impact factor: 8.317

7.  P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD).

Authors:  Joachim Roesler; Florian Segerer; Henner Morbach; Stefan Kleinert; Sebastian Thieme; Angela Rösen-Wolff; Johannes G Liese
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

8.  Hematopoietic stem cell transplantation from matched unrelated donors in chronic granulomatous disease.

Authors:  C Schuetz; M Hoenig; S Gatz; F Speth; U Benninghoff; A Schulz; K M Debatin; W Friedrich
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.